Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IDE849

Antibody-drug conjugate · Cytotoxic, directed at delta-like protein 3 (DLL3) · developed by IDEAYA Biosciences

Phase 1/2 Most advanced trial
IDYA Developer
1 Registered trials

What is IDE849?

IDE849 is an antibody-drug conjugate made of a humanized IgG1 antibody that binds DLL3, a Notch pathway protein overexpressed on tumor cells, linked by a cleavable linker to a topoisomerase I inhibitor. After binding and internalization, the payload is released and inhibits DNA replication, causing tumor cell death. It is being studied in small-cell lung cancer, neuroendocrine carcinomas and other DLL3-expressing solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
delta-like protein 3 (DLL3)
Mechanism
Cytotoxic, directed at delta-like protein 3 (DLL3)
Pathways
Notch signaling, DNA replication inhibition, cell cycle arrest, apoptosis, bystander effect
Therapy area
Oncology
Developer
IDEAYA Biosciences (IDYA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07174583 Phase 1/2 Small-cell Lung Cancer Recruiting IDYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neuroendocrine CarcinomasSmall-cell Lung CancerSolid Tumor Show to Express DLL3

Other drugs acting on DLL3

More from IDEAYA Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.

Follow IDYA, the company behind IDE849

See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IDYA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.